Clinical pharmacokinetic and Pharmacodynamic considerations in the (modern) treatment of melanoma
HY Kim, PJ Upadhyay, A Fahmy, X Liu… - Clinical …, 2019 - Springer
Targeted therapies, based on identification of common oncogenic mutations such as BRAF
V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of …
V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of …
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma.
HY Kim, PJ Upadhyay, A Fahmy, X Liu… - Clinical …, 2019 - europepmc.org
Targeted therapies, based on identification of common oncogenic mutations such as BRAF
V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of …
V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of …
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
HY Kim, PJ Upadhyay, A Fahmy, X Liu… - Clinical …, 2019 - search.proquest.com
Dual mitogen-activated protein kinase (MAPK) pathway inhibition of BRAF V600E/K and
MEK 1/2 kinases with BRAF-MEK inhibitors using dabrafenib-trametinib, vemurafenib …
MEK 1/2 kinases with BRAF-MEK inhibitors using dabrafenib-trametinib, vemurafenib …
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
HY Kim, PJ Upadhyay, A Fahmy… - Clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
Targeted therapies, based on identification of common oncogenic mutations such as BRAF
V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of …
V600E/K and monoclonal antibody immunotherapies, have transformed the treatment of …